From our current study, topical melatonin treatment improved the skin inflammation and thickening in a mouse model of AD, which is potentially due to regulation of inflammatory cytokines and chemokines including IP-10, MCP-1, CCL-27, and IL-4, and reduction of cytokine-induced cell proliferation. This evidence concerns the gene CCL2 and dermatitis.